Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators.

Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18.

PMID:
25701170
2.

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators.

Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.

PMID:
25601341
3.

Radical prostatectomy or watchful waiting in early prostate cancer.

Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Spångberg A, Andrén O, Palmgren J, Steineck G, Adami HO, Johansson JE.

N Engl J Med. 2014 Mar 6;370(10):932-42. doi: 10.1056/NEJMoa1311593.

4.

Prostate biopsy sampling causes hematogenous dissemination of epithelial cellular material.

Ladjevardi S, Auer G, Castro J, Ericsson C, Zetterberg A, Häggman M, Wiksell H, Jorulf H.

Dis Markers. 2014;2014:707529. doi: 10.1155/2014/707529. Epub 2014 Jan 28.

5.

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.

Armstrong AJ, Häggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle Ö, Forsberg G, Carducci MA, Pili R.

Clin Cancer Res. 2013 Dec 15;19(24):6891-901. doi: 10.1158/1078-0432.CCR-13-1581. Epub 2013 Nov 19.

6.

Abiraterone in metastatic prostate cancer without previous chemotherapy.

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators.

N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.

7.

MR spectroscopy of the human prostate using surface coil at 3 T: metabolite ratios, age-dependent effects, and diagnostic possibilities.

Weis J, Jorulf H, Bergman A, Ortiz-Nieto F, Häggman M, Ahlström H.

J Magn Reson Imaging. 2011 Dec;34(6):1277-84. doi: 10.1002/jmri.22746. Epub 2011 Sep 23.

PMID:
21954046
8.

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ.

J Clin Oncol. 2011 Oct 20;29(30):4022-8. doi: 10.1200/JCO.2011.35.6295. Epub 2011 Sep 19.

9.

Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M, Bill-Axelson A; SPCG-4 Investigators.

Lancet Oncol. 2011 Sep;12(9):891-9. doi: 10.1016/S1470-2045(11)70162-0. Epub 2011 Aug 5.

PMID:
21821474
10.

Radical prostatectomy versus watchful waiting in early prostate cancer.

Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson JE; SPCG-4 Investigators.

N Engl J Med. 2011 May 5;364(18):1708-17. doi: 10.1056/NEJMoa1011967.

12.

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.

Bratt O, Häggman M, Ahlgren G, Nordle O, Björk A, Damber JE.

Br J Cancer. 2009 Oct 20;101(8):1233-40. doi: 10.1038/sj.bjc.6605322. Epub 2009 Sep 15.

13.

Personalized prediction of tumor response and cancer progression on prostate needle biopsy.

Donovan MJ, Khan FM, Fernandez G, Mesa-Tejada R, Sapir M, Zubek VB, Powell D, Fogarasi S, Vengrenyuk Y, Teverovskiy M, Segal MR, Karnes RJ, Gaffey TA, Busch C, Haggman M, Hlavcak P, Freedland SJ, Vollmer RT, Albertsen P, Costa J, Cordon-Cardo C.

J Urol. 2009 Jul;182(1):125-32. doi: 10.1016/j.juro.2009.02.135. Epub 2009 May 17.

PMID:
19450827
14.

Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.

Johansson E, Bill-Axelson A, Holmberg L, Onelöv E, Johansson JE, Steineck G; Scandinavian Prostate Cancer Group Study No 4.

Eur Urol. 2009 Feb;55(2):422-30. doi: 10.1016/j.eururo.2008.08.054. Epub 2008 Sep 2.

PMID:
18783877
15.

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE; Scandinavian Prostate Cancer Group Study Number 4.

J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54. doi: 10.1093/jnci/djn255. Epub 2008 Aug 11.

16.

Two-dimensional spectroscopic imaging for pretreatment evaluation of prostate cancer: comparison with the step-section histology after radical prostatectomy.

Weis J, Ahlström H, Hlavcak P, Häggman M, Ortiz-Nieto F, Bergman A.

Magn Reson Imaging. 2009 Jan;27(1):87-93. doi: 10.1016/j.mri.2008.05.010. Epub 2008 Jul 3.

PMID:
18599244
17.

"Between Men": a psychosocial rehabilitation programme for men with prostate cancer.

Berglund G, Petersson LM, Eriksson KC, Wallenius I, Roshanai A, Nordin KM, Sjödén PO, Häggman M.

Acta Oncol. 2007;46(1):83-9.

PMID:
17438709
18.

Prediction of percent Gleason grade 4/5 by multiple core biopsies.

Glaessgen A, Busch C, Norberg M, Häggman M, Nilsson B, Egevad L.

Scand J Urol Nephrol. 2006;40(6):465-71.

PMID:
17130098
19.
20.

The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer.

Häggarth L, Auer G, Busch C, Norberg M, Häggman M, Egevad L.

Scand J Urol Nephrol. 2005;39(5):387-92.

PMID:
16257840
Items per page

Supplemental Content

Loading ...
Write to the Help Desk